According to the China Food and Drug Administration regulation No. 24, which announced the "Drug Instruction and Labeling Regulations", after the drug instruction is approved for revision, the drug manufacturer shall immediately notify the relevant drug business enterprises, user units and other departments of the revised content. In order to enable the relevant units and medical & health professionals to obtain the latest information on the instructions in a timely manner, our company is required to publish the latest approved information on the instructions.

 (Only listed products in mainland China)